Interference of confounding factors on the use of (1,3)-beta-D-glucan in the diagnosis of invasive candidiasis in the intensive care unit

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 34, Issue 2, 2015, Pages 357-365

  Lo Cascio, G ^a   Koncan, R ^b   Stringari, G ^b   Russo, A ^b   Azzini, A ^b   Ugolini, A ^b   Ligozzi, M ^b   Polati, E ^b   Cornaglia, G ^b   Concia, E ^b   Schweiger, V ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCANASE; ALBUMIN; BIOLOGICAL MARKER; CORTICOSTEROID; FLUCONAZOLE; FRESH FROZEN PLASMA; IMMUNOGLOBULIN G; ITRACONAZOLE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; THROMBOCYTE CONCENTRATE; VANCOMYCIN; VORICONAZOLE; ANTIFUNGAL AGENT; BETA GLUCAN; BETA-1,3-D-GLUCAN; FUNGUS ANTIGEN; IMMUNOGLOBULIN; SERUM ALBUMIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE KIDNEY FAILURE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC THERAPY; ARTICLE; BONE MARROW APLASIA; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME BLOOD LEVEL; ERYTHROCYTE CONCENTRATE; FALSE NEGATIVE RESULT; FEMALE; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFECTION RISK; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; LEUKEMIA; LEUKOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PANCYTOPENIA; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TOTAL PARENTERAL NUTRITION; AGED; BLOOD; CANDIDA; CANDIDIASIS, INVASIVE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; REPRODUCIBILITY;

AGED; ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; BETA-GLUCANS; CANDIDA; CANDIDIASIS, INVASIVE; FEMALE; HUMANS; IMMUNOGLOBULINS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN;

EID: 84921808381     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-014-2239-z     Document Type: Article

References (35)

1. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K; EPIC II Group of Investigators (2009) International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323–2329
2. Kett DH, Azoulay E, Echeverria PM, Vincent JL; Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators (2011) Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 39:665–670
3. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M (1995) The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274:639–644
4. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP; National Nosocomial Infections Surveillance System Hospitals (2002) Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 35:627–630
5. Tortorano AM, Dho G, Prigitano A, Breda G, Grancini A, Emmi V, Cavanna C, Marino G, Morero S, Ossi C, Delvecchio G, Passera M, Cusumano V, David A, Bonaccorso G, Corona A, Favaro M, Vismara C, Garau MG, Falchi S, Tejada MR; ECMM-FIMUA Study Group (2012) Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006–2008). Mycoses 55:73–79
6. Concia E, Azzini AM, Conti M (2009) Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients. Drugs 69:5–14
7. Arendrup MC (2010) Epidemiology of invasive candidiasis. Curr Opin Crit Care 16:445–452
8. Prowle JR, Echeverri JE, Ligabo EV, Sherry N, Taori GC, Crozier TM, Hart GK, Korman TM, Mayall BC, Johnson PD, Bellomo R (2011) Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality. Crit Care 15:R100
9. Viudes A, Pemán J, Cantón E, Ubeda P, López-Ribot JL, Gobernado M (2002) Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 21:767–774
10. Bregenzer T, Evison-Eckstein AC, Frei R, Zimmerli W (1996) Clinical aspects and prognosis of candidemia, a 6-year retrospective study. Schweiz Med Wochenschr 126:1829–1833
11. Pemán J, Zaragoza R (2010) Current diagnostic approaches to invasive candidiasis in critical care settings. Mycoses 53:424–433
12. Montagna MT, Caggiano G, Borghi E, Morace G (2009) The role of the laboratory in the diagnosis of invasive candidiasis. Drugs 69:59–63
13. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L (2004) Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39:199–205
14. Obayashi T, Yoshida M, Mori T, Goto H, Yasuoka A, Iwasaki H, Teshima H, Kohno S, Horiuchi A, Ito A, Yamaguchi H (1995) Plasma (1→3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 345:17–20
15. Ellis M, Al-Ramadi B, Finkelman M, Hedstrom U, Kristensen J, Ali-Zadeh H, Klingspor L (2008) Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol 57:287–295
16. Racil Z, Kocmanova I, Lengerova M, Weinbergerova B, Buresova L, Toskova M, Winterova J, Timilsina S, Rodriguez I, Mayer J (2010) Difficulties in using 1,3-β-D-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies—high frequency of false-positive results and their analysis. J Med Microbiol 59:1016–1022
17. Metan G, Ağkuş C, Buldu H, Koç AN (2010) The interaction between piperacillin/tazobactam and assays for Aspergillus galactomannan and 1,3-beta-D-glucan in patients without risk factors for invasive fungal infections. Infection 38:217–221
18. Koo S, Bryar JM, Page JH, Baden LR, Marty FM (2009) Diagnostic performance of the (1→3)-beta-D-glucan assay for invasive fungal disease. Clin Infect Dis 49:1650–1659
19. Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi MA, Bello G, Maviglia R, Fadda G, Sanguinetti M, Antonelli M (2011) Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score and colonization index. Crit Care 15:R249–R259
20. Del Bono V, Delfino E, Furfaro E, Mikulska M, Nicco E, Bruzzi P, Mularoni A, Bassetti M, Viscoli C (2011) Clinical performance of the (1,3)-β-D-glucan assay in early diagnosis of nosocomial candida bloodstream infections. Clin Vaccine Immunol 18:2113–2117
21. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R, Tamura H, Finkelman MA, Rex JH (2005) Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41:654–659
22. Nagasawa K, Yano T, Kitabayashi G, Morimoto H, Yamada Y, Ohata A, Usami M, Horiuchi T (2003) Experimental proof of contamination of blood components by (1→3)-beta-D-glucan caused by filtration with cellulose filters in the manufacturing process. J Artif Organs 6:49–54
23. Kanda H, Kubo K, Hamasaki K, Kanda Y, Nakao A, Kitamura T, Fujita T, Yamamoto K, Mimura T (2001) Influence of various hemodialysis membranes on the plasma (1→3)-beta-D-glucan level. Kidney Int 60:319–323
24. Nakao A, Yasui M, Kawagoe T, Tamura H, Tanaka S, Takagi H (1997) False-positive endotoxemia derives from gauze glucan after hepatectomy for hepatocellular carcinoma with cirrhosis. Hepatogastroenterology 44:1413–1418
25. Mennink-Kersten MA, Warris A, Verweij PE (2006) 1,3-beta-D-glucan in patients receiving intravenous amoxicillin–clavulanic acid. N Engl J Med 345:2834–2835
26. Metan G, Agkus C, Nedret Koc A, Elmali F, Finkelman MA (2012) Does ampicillin–sulbactam cause false positivity of (1,3)-beta-D-glucan assay? A prospective evaluation of 15 patients without invasive fungal infections. Mycoses 55:366–371
27. Mennink-Kersten MA, Ruegebrink D, Verweij PE (2008) Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis 46:1930–1931
28. Albert O, Toubas D, Strady C, Cousson J, Delmas C, Vernet V, Villena I (2011) Reactivity of (1→3)-β-d-glucan assay in bacterial bloodstream infections. Eur J Clin Microbiol Infect Dis 30:1453–1460
29. Metan G, Koç AN, Ağkuş Ç, Kaynar LG, Alp E, Eser B (2012) Can bacteraemia lead to false positive results in 1,3-beta-d-glucan test? Analysis of 83 bacteraemia episodes in high-risk patients for invasive fungal infections. Rev Iberoam Micol 29:169–171
30. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ; ESCMID Fungal Infection Study Group (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):19–37
31. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7–14
32. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–1821
33. Budhavari S (2009) What’s new in diagnostics? Fungitell®: 1,3 beta-D glucan assay. South Afr J Epidemiol Infect 24:37–38
34. Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C (2011) Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One 6:e24198
35. Onishi A, Sugiyama D, Kogata Y, Saegusa J, Sugimoto T, Kawano S, Morinobu A, Nishimura K, Kumagai S (2012) Diagnostic accuracy of serum 1,3-β-D-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol 50:7–15